

Corey S Cutler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1786416/publications.pdf>

Version: 2024-02-01

270
papers

24,105
citations

8181

76
h-index

8167

148
g-index

278
all docs

278
docs citations

278
times ranked

16054
citing authors

#	ARTICLE	IF	CITATIONS
1	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 389-401.e1.	2.0	2,636
2	Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2011, 365, 2055-2066.	27.0	996
3	Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors. <i>New England Journal of Medicine</i> , 2012, 367, 1487-1496.	27.0	762
4	A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. <i>Blood</i> , 2004, 104, 579-585.	1.4	638
5	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017, 376, 536-547.	27.0	586
6	Risk factors for acute GVHD and survival after hematopoietic cell transplantation. <i>Blood</i> , 2012, 119, 296-307.	1.4	559
7	Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. <i>Blood</i> , 2011, 118, 282-288.	1.4	549
8	First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1150-1163.	2.0	506
9	Ipilimumab for Patients with Relapse after Allogeneic Transplantation. <i>New England Journal of Medicine</i> , 2016, 375, 143-153.	27.0	488
10	Rituximab for steroid-refractory chronic graft-versus-host disease. <i>Blood</i> , 2006, 108, 756-762.	1.4	422
11	Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease. <i>Science Translational Medicine</i> , 2013, 5, 179ra43.	12.4	401
12	Acute and Chronic Graft-Versus-Host Disease After Allogeneic Peripheral-Blood Stem-Cell and Bone Marrow Transplantation: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2001, 19, 3685-3691.	1.6	396
13	Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. <i>Blood</i> , 2007, 109, 4586-4588.	1.4	395
14	Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. <i>Blood</i> , 2005, 105, 2973-2978.	1.4	361
15	Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 2691-2698.	1.6	359
16	Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. <i>Blood</i> , 2017, 130, 2243-2250.	1.4	352
17	Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 266-274.	2.0	331
18	Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. <i>Blood</i> , 2011, 117, 4651-4657.	1.4	319

#	ARTICLE	IF	CITATIONS
19	Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients. <i>Science Translational Medicine</i> , 2012, 4, 117ra7.	12.4	312
20	A disease risk index for patients undergoing allogeneic stem cell transplantation. <i>Blood</i> , 2012, 120, 905-913.	1.4	310
21	Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. <i>Blood</i> , 2003, 102, 1578-1582.	1.4	299
22	Double Unrelated Reduced-Intensity Umbilical Cord Blood Transplantation in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 82-89.	2.0	294
23	Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. <i>Blood</i> , 2009, 113, 3865-3874.	1.4	285
24	Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. <i>Blood</i> , 2005, 105, 1810-1814.	1.4	280
25	Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. <i>Blood</i> , 2013, 122, 3074-3081.	1.4	280
26	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 1753-1762.	1.4	278
27	Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 2662-2670.	1.6	265
28	High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host Disease. <i>Clinical Cancer Research</i> , 2007, 13, 6107-6114.	7.0	238
29	Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. <i>Journal of Clinical Investigation</i> , 2010, 120, 1479-1493.	8.2	212
30	Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. <i>Blood</i> , 2011, 118, 4242-4249.	1.4	196
31	Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. <i>Blood</i> , 2004, 104, 1559-1564.	1.4	193
32	Impact of Conditioning Regimen Intensity on Outcome of Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1047-1055.	2.0	181
33	Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. <i>Blood</i> , 2011, 118, 6691-6697.	1.4	180
34	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. <i>Blood</i> , 2014, 123, 3988-3998.	1.4	179
35	Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. <i>Blood</i> , 2014, 124, 1372-1377.	1.4	178
36	Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. <i>Blood</i> , 2007, 109, 3108-3114.	1.4	177

#	ARTICLE	IF	CITATIONS
37	Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1262-1273.	2.0	176
38	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. <i>Blood</i> , 2016, 128, 130-137.	1.4	176
39	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2014, 124, 4867-4876.	8.2	173
40	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. <i>Blood</i> , 2017, 129, 2186-2197.	1.4	156
41	Sirolimus and Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 551-557.	2.0	153
42	Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. <i>Blood</i> , 2008, 112, 4425-4431.	1.4	153
43	Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. <i>Blood</i> , 2003, 102, 1601-1605.	1.4	151
44	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. <i>Blood</i> , 2016, 127, 2144-2154.	1.4	145
45	Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. <i>Blood</i> , 2016, 127, 646-657.	1.4	145
46	Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2004, 104, 1224-1226.	1.4	140
47	Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 328-336.	2.0	136
48	Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. <i>Blood</i> , 2007, 110, 490-500.	1.4	136
49	Bortezomib-Based Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 3202-3208.	1.6	135
50	Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. <i>Blood</i> , 2011, 117, 6714-6720.	1.4	128
51	B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. <i>Blood</i> , 2012, 120, 2529-2536.	1.4	126
52	Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. <i>JCI Insight</i> , 2016, 1, e89278.	5.0	126
53	Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. <i>Blood</i> , 2021, 138, 2278-2289.	1.4	124
54	Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1796-1803.	2.0	123

#	ARTICLE	IF	CITATIONS
55	Biomarker Panel for Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2016, 34, 2583-2590.	1.6	118
56	Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 882-896.	2.0	117
57	Efficacy of Rituximab in the Setting of Steroid-Refractory Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1005-1013.	2.0	116
58	Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. <i>Blood</i> , 2011, 117, 2275-2283.	1.4	115
59	Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 449-455.	2.0	113
60	Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation. <i>JAMA Oncology</i> , 2016, 2, 1583.	7.1	110
61	Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning. <i>Journal of Clinical Oncology</i> , 2008, 26, 5767-5774.	1.6	105
62	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1343-1359.	2.0	105
63	Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. <i>Blood</i> , 2013, 122, 1510-1517.	1.4	104
64	Voriconazole and Sirolimus Coadministration after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 552-559.	2.0	102
65	Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. <i>Blood</i> , 2012, 120, 2545-2552.	1.4	101
66	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 4085-4094.	1.4	101
67	Mucositis after Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study of Methotrexate- and Non-Methotrexate-Containing Graft-versus-Host Disease Prophylaxis Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 383-388.	2.0	98
68	Iron Overload in Patients with Acute Leukemia or MDS Undergoing Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 852-860.	2.0	98
69	Mechanistic approaches for the prevention and treatment of chronic GVHD. <i>Blood</i> , 2017, 129, 22-29.	1.4	98
70	Costs of Allogeneic Hematopoietic Cell Transplantation with High-Dose Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 197-207.	2.0	95
71	Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). <i>Blood</i> , 2013, 122, 1974-1982.	1.4	92
72	Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. <i>Blood</i> , 2016, 127, 2489-2497.	1.4	92

#	ARTICLE	IF	CITATIONS
73	Peripheral Blood Stem Cells for Allogeneic Transplantation: A Review. <i>Stem Cells</i> , 2001, 19, 108-117.	3.2	89
74	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	5.2	89
75	B Cells in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 16-23.	2.0	86
76	Prediction of Veno-Occlusive Disease Using Biomarkers of Endothelial Injury. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1180-1185.	2.0	85
77	Î±1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. <i>Blood</i> , 2018, 131, 1372-1379.	1.4	81
78	Improved survival after acute graft- <i>versus</i> -host disease diagnosis in the modern era. <i>Haematologica</i> , 2017, 102, 958-966.	3.5	79
79	Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired inÂAdvanced Age. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 792-800.	2.0	76
80	Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics postâ€“allogeneic HCT. <i>Blood</i> , 2017, 129, 162-170.	1.4	75
81	Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2021, 39, 3328-3339.	1.6	72
82	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 545-557.	1.2	72
83	Prior rituximab correlates with less acute graftâ€“versusâ€“host disease and better survival in Bâ€“cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. <i>British Journal of Haematology</i> , 2009, 145, 816-824.	2.5	66
84	Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2002-2007.	2.0	64
85	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	5.2	63
86	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. <i>Blood</i> , 2020, 135, 2182-2191.	1.4	62
87	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 817-835.	1.2	62
88	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016, 34, 1864-1871.	1.6	61
89	Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. <i>Blood Advances</i> , 2021, 5, 352-364.	5.2	58
90	Use of Matched Unrelated Donors Compared with Matched Related Donors Is Associated with Lower Relapse and Superior Progression-Free Survival after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1196-1204.	2.0	57

#	ARTICLE	IF	CITATIONS
91	Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 873-880.	2.0	56
92	Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease Prophylaxis after Reduced-Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 844-850.	2.0	55
93	Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2020, 130, 4624-4636.	8.2	55
94	The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. <i>British Journal of Haematology</i> , 2016, 173, 96-104.	2.5	53
95	An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. <i>JCI Insight</i> , 2017, 2, .	5.0	53
96	An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2017, 130, 360-367.	1.4	52
97	Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019, 3, 2199-2204.	5.2	52
98	Sirolimus, Tacrolimus, and Low-Dose Methotrexate as Graft-versus-Host Disease Prophylaxis in Related and Unrelated Donor Reduced-Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 920-926.	2.0	50
99	Should Methotrexate plus Calcineurin Inhibitors Be Considered Standard of Care for Prophylaxis of acute Graft-versus-Host Disease?. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, S18-S27.	2.0	48
100	A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1737-1743.	2.0	48
101	Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	48
102	Donor-Derived Second Hematologic Malignancies after Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1025-1031.	2.0	47
103	Clinical Benefit of Response in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1517-1524.	2.0	47
104	Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 668-675.	2.0	45
105	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , 2016, 122, 3005-3014.	4.1	45
106	Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. <i>Blood</i> , 2011, 118, 5021-5030.	1.4	44
107	Rituximab for prevention and treatment of graft-versus-host disease. <i>International Journal of Hematology</i> , 2011, 93, 578-585.	1.6	44
108	Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. <i>Blood Advances</i> , 2019, 3, 2550-2561.	5.2	44

#	ARTICLE	IF	CITATIONS
109	Machine learning reveals chronic graft-versus-host disease phenotypes and stratifies survival after stem cell transplant for hematologic malignancies. <i>Haematologica</i> , 2019, 104, 189-196.	3.5	44
110	Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34 ⁺ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2016, 101, 499-505.	3.5	43
111	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. <i>Blood</i> , 2016, 128, 2350-2358.	1.4	43
112	Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 253-265.	2.5	40
113	Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update. <i>Current Opinion in Hematology</i> , 2010, 17, 500-504.	2.5	39
114	Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome. <i>JAMA Oncology</i> , 2020, 6, 486.	7.1	39
115	Chronic graft-versus-host disease. <i>Current Opinion in Oncology</i> , 2006, 18, 126-131.	2.4	38
116	Current and novel therapies in acute GVHD. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 223-237.	1.7	37
117	Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2344-2353.	2.0	37
118	Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 137-144.	2.0	36
119	Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. <i>Blood Advances</i> , 2021, 5, 4278-4284.	5.2	36
120	High-resolution HLA matching in double umbilical cord blood reduced intensity transplantation in adults. <i>Transfusion</i> , 2009, 49, 995-1002.	1.6	34
121	A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. <i>Haematologica</i> , 2018, 103, 1915-1924.	3.5	34
122	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.	2.0	33
123	Improving outcomes in umbilical cord blood transplantation: State of the art. <i>Blood Reviews</i> , 2012, 26, 241-246.	5.7	32
124	Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 910-918.	2.0	32
125	Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. <i>Blood Advances</i> , 2019, 3, 969-979.	5.2	32
126	Review of Stem-Cell Transplantation for Myelodysplastic Syndromes in Older Patients in the Context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome Emanating From the Centers for Medicare and Medicaid Services. <i>Journal of Clinical Oncology</i> , 2011, 29, 566-572.	1.6	31

#	ARTICLE	IF	CITATIONS
127	Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2017, 102, 1185-1191.	3.5	31
128	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 729-737.	1.2	29
129	A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1907-1913.	2.0	27
130	A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. <i>Haematologica</i> , 2016, 101, 1251-1259.	3.5	27
131	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , 2018, 2, 1882-1888.	5.2	27
132	Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. <i>Blood Advances</i> , 2021, 5, 975-983.	5.2	27
133	The clinical and functional effects of TERT variants in myelodysplastic syndrome. <i>Blood</i> , 2021, 138, 898-911.	1.4	27
134	An Overview of Hematopoietic Stem Cell Transplantation. <i>Clinics in Chest Medicine</i> , 2005, 26, 517-527.	2.1	26
135	Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2019, 3, 4136-4146.	5.2	26
136	Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. <i>Blood</i> , 2020, 136, 3070-3081.	1.4	25
137	Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and Methods. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1566-1572.	2.0	24
138	Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. <i>Haematologica</i> , 2015, 100, 1222-1227.	3.5	24
139	Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 393-399.	2.0	24
140	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. <i>Blood</i> , 2021, 137, 3212-3217.	1.4	24
141	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 452-466.	1.2	24
142	Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 640-645.	2.0	23
143	COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. <i>Blood Advances</i> , 2021, 5, 861-871.	5.2	23
144	Poor Agreement between Clinician Response Ratings and Calculated Response Measures in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1649-1655.	2.0	22

#	ARTICLE	IF	CITATIONS
145	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Advances, 2020, 4, 4113-4123.	5.2	22
146	IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults. PLoS ONE, 2015, 10, e0132564.	2.5	22
147	Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndrome. Hematology American Society of Hematology Education Program, 2010, 2010, 325-329.	2.5	21
148	Mammalian Target of Rapamycin Inhibitor-Associated Stomatitis in Hematopoietic Stem Cell Transplantation Patients Receiving Sirolimus Prophylaxis for Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 503-508.	2.0	21
149	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood, 2019, 133, 94-99.	1.4	21
150	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 632-641.	1.2	21
151	Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. Blood Advances, 2021, 5, 5140-5149.	5.2	21
152	Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. Biology of Blood and Marrow Transplantation, 2019, 25, 599-605.	2.0	20
153	A multicenter, retrospective, case-cohort study of the epidemiology and risk factors for Clostridium difficile infection among cord blood transplant recipients. Transplant Infectious Disease, 2017, 19, e12728.	1.7	19
154	Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis. Biology of Blood and Marrow Transplantation, 2019, 25, 451-458.	2.0	19
155	Phase I Study of Alemtuzumab for Therapy of Steroid-Refractory Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2013, 19, 804-811.	2.0	18
156	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Advances, 2020, 4, 3180-3190.	5.2	18
157	Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. Blood, 2017, 130, 2889-2899.	1.4	17
158	Outcomes and management strategies for graft failure after umbilical cord blood transplantation. American Journal of Hematology, 2014, 89, 1097-1101.	4.1	16
159	An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 2084-2091.	2.0	16
160	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2017, 23, 971-979.	2.0	16
161	Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. Blood Advances, 2017, 1, 2269-2279.	5.2	16
162	Disability Related to Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2020, 26, 772-777.	2.0	16

#	ARTICLE	IF	CITATIONS
163	BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Advances, 2020, 4, 1881-1893.	5.2	16
164	Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience. Transplantation and Cellular Therapy, 2021, 27, 990.e1-990.e7.	1.2	16
165	A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS. Blood, 2011, 118, 115-115.	1.4	16
166	Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force. Transplantation and Cellular Therapy, 2022, 28, 426-445.	1.2	16
167	Novel Drugs for the Prevention and Treatment of Acute GVHD. Current Pharmaceutical Design, 2008, 14, 1962-1973.	1.9	15
168	Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica, 2014, 99, 1499-1508.	3.5	15
169	Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials) Tj ETQq1 1 0.784314 rgBT /Overlock	2.9	15
170	Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplantation, 2021, 56, 1006-1012.	2.4	15
171	Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica, 2021, 106, 3219-3222.	3.5	15
172	Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant. Blood Advances, 2022, 6, 181-188.	5.2	15
173	Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 529-539.	2.0	14
174	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. Blood, 2020, 135, 28-40.	1.4	14
175	A positive psychology intervention to promote health outcomes in hematopoietic stem cell transplantation: the PATH proof-of-concept trial. Bone Marrow Transplantation, 2021, 56, 2276-2279.	2.4	14
176	Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1776-1782.	2.0	13
177	Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy, 2017, 19, 272-284.	0.7	13
178	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. Blood Advances, 2018, 2, 1022-1031.	5.2	13
179	Generic Immunosuppressants in Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 285-290.	2.0	12
180	GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood Advances, 2022, 6, 2183-2194.	5.2	12

#	ARTICLE	IF	CITATIONS
181	Yin and Yang of Psychological Health in the Cancer Experience: Does Positive Psychology Have a Role?. <i>Journal of Clinical Oncology</i> , 2022, 40, 2402-2407.	1.6	12
182	Disseminated varicella-zoster virus infections following messenger RNA-based COVID-19 vaccination. <i>JAAD Case Reports</i> , 2021, 17, 126-129.	0.8	11
183	Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213). <i>Blood</i> , 2020, 136, 45-46.	1.4	11
184	Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age. <i>Blood</i> , 2015, 126, 193-193.	1.4	11
185	GVHD Prevention: An Ounce Is Better Than a Pound. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S17-S26.	2.0	10
186	Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 77-81.	2.5	10
187	Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 126-133.	2.0	10
188	Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells. <i>Clinical Immunology</i> , 2019, 207, 18-23.	3.2	10
189	A Phase I/II Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT). <i>Blood</i> , 2018, 132, 705-705.	1.4	10
190	Association Of Graft Vs. Host Disease (GVHD) With a Lower Relapse/Progression Rate After Allogeneic Hemopoietic Stem Cell Transplantation (HSCT) With Reduced Intensity Conditioning In Patients With Follicular and Mantle Cell Lymphoma: A CIBMTR Analysis. <i>Blood</i> , 2013, 122, 2093-2093.	1.4	10
191	The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. <i>Haematologica</i> , 2023, 108, 150-160.	3.5	10
192	Transplantation for therapy-related, TP53-mutated myelodysplastic syndrome – not because we can, but because we should. <i>Haematologica</i> , 2017, 102, 1970-1971.	3.5	9
193	Economic and Practical Considerations in the Treatment of Oral Mucosal Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1748-1753.	2.0	9
194	Targeting PI3K function for amelioration of murine chronic graft-versus-host disease. <i>American Journal of Transplantation</i> , 2019, 19, 1820-1830.	4.7	9
195	Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. <i>Blood Advances</i> , 2021, 5, 4549-4559.	5.2	8
196	Patient Selection for Transplantation in the Myelodysplastic Syndromes. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 469-476.	2.2	7
197	A novel TERC CR4/CR5 domain mutation causes telomere disease via decreased TERT binding. <i>Blood</i> , 2016, 128, 2089-2092.	1.4	7
198	Chronic Graft-Versus-Host Disease After Allogeneic Peripheral-Blood Stem-Cell Transplantation: A Little Methotrexate Goes a Long Way. <i>Journal of Clinical Oncology</i> , 2002, 20, 603-606.	1.6	6

#	ARTICLE	IF	CITATIONS
199	The Anatomic Distribution of Skin Involvement in Patients with Incident Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 279-286.	2.0	6
200	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	2.4	6
201	Impact of conditioning regimen intensity on the outcomes of peripheral Tâ€cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic Tâ€cell lymphoma patients undergoing allogeneic transplant. <i>British Journal of Haematology</i> , 2022, 197, 212-222.	2.5	6
202	Invasive Yeast Infection after Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndrome. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 508.e1-508.e8.	1.2	6
203	Choroidal Metastases. <i>Journal of Clinical Oncology</i> , 1999, 17, 3358-3359.	1.6	5
204	Transplantation for MDS in the Elderly: More Evidence, or More Bias?. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1320-1321.	2.0	5
205	Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?. <i>Leukemia</i> , 2021, 35, 1166-1175.	7.2	5
206	Sirolimus, Tacrolimus and Reduced-Dose Methotrexate as Graft Versus Host Disease (GVHD) Prophylaxis after Non-Myeloablative Stem Cell Transplantation: Low Incidence of Acute GVHD Compared with Tacrolimus/Methotrexate or Cyclosporine/Prednisone.. <i>Blood</i> , 2004, 104, 730-730.	1.4	5
207	Outcome and Prognostic Factors for Patients Who Relapse After Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2012, 120, 3069-3069.	1.4	5
208	Reprint of: B Cells in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S11-S18.	2.0	4
209	Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 103-112.	2.0	4
210	The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2468-2473.	2.0	4
211	Long-Term Utilization Patterns of Topical Therapy and Clinical Outcomes of Oral Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 373-379.	2.0	4
212	Use of Prescription Sialagogues for Management of Xerostomia in Chronic Graft-versus-Host-Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 480.e1-480.e5.	1.2	4
213	Functional Effects of Low-Dose IL-2 in Patients with Chronic Graft Versus Host Disease. <i>Blood</i> , 2016, 128, 667-667.	1.4	4
214	Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 406.e1-406.e6.	1.2	4
215	Peer support in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT): a qualitative study. <i>Bone Marrow Transplantation</i> , 2022, 57, 1277-1286.	2.4	4
216	Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2164-2165.	2.0	3

#	ARTICLE	IF	CITATIONS
217	Oral health in allogeneic hematopoietic stem cells transplantation survivors. Bone Marrow Transplantation, 2020, 55, 2211-2214.	2.4	3
218	Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens.. Blood, 2004, 104, 351-351.	1.4	3
219	HLA-C Mismatch Is Associated with Inferior Outcome after Unrelated Donor Non-Myeloablative Hematopoietic Stem Cell Transplantation.. Blood, 2005, 106, 835-835.	1.4	3
220	Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation. Blood, 2012, 120, 311-311.	1.4	3
221	Impact Of Umbilical Cord Unit Banking Conditions On Clinical Outcomes In Double Cord Transplant Recipients. Blood, 2013, 122, 695-695.	1.4	3
222	Bortezomib-Based Versus Standard of Care Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation: A Phase II Randomized Controlled Trial. Blood, 2016, 128, 508-508.	1.4	3
223	Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease. Blood, 2021, 138, 264-264.	1.4	3
224	The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era. Current Hematologic Malignancy Reports, 2006, 1, 160-167.	2.3	2
225	Topical sirolimus for management of refractory oral chronic graft-versus-host disease. Oral Diseases, 2021, 27, 1451-1454.	3.0	2
226	Sirolimus and Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation.. Blood, 2004, 104, 1834-1834.	1.4	2
227	Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis.. Blood, 2004, 104, 2251-2251.	1.4	2
228	Prognostic Impact of Elevated Serum Ferritin in Patients Undergoing Myeloablative Stem Cell Transplantation.. Blood, 2006, 108, 595-595.	1.4	2
229	Prior Therapy with Rituximab Correlates with Less Acute Graft-Versus-Host Disease and Better Survival in B-Cell Lymphoma Patients Who Received Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).. Blood, 2007, 110, 1063-1063.	1.4	2
230	Similar Outcome of Non-Myeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients Greater Than Fifty Years of Age.. Blood, 2004, 104, 300-300.	1.4	2
231	Phase I Multicenter Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-Vs.-Host Disease (GVHD). Blood, 2015, 126, 1930-1930.	1.4	2
232	Are We Making PROGRESS in Preventing Graft-versus-Host Disease and Improving Clinical Outcomes? Impact of BMT CTN 1301 Study Results on Clinical Practice. Transplantation and Cellular Therapy, 2022, 28, 419-425.	1.2	2
233	In response to "American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults". Blood Advances, 2020, 4, 5431-5432.	5.2	1
234	Stem Cell Sources. , 2004, , 337-356.		1

#	ARTICLE	IF	CITATIONS
235	Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem-Cell Transplantation: A Post-Hoc Analysis of a Randomized Controlled Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate (BMT CTN 0402). <i>Blood</i> , 2018, 132, 2110-2110.	1.4	1
236	Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation.. <i>Blood</i> , 2006, 108, 259-259.	1.4	1
237	Risk of HHV6-Associated Post-Transplant Acute Limbic Encephalitis (PALE) after Umbilical Cord Blood Stem Cell Transplantation: A Cohort Analysis.. <i>Blood</i> , 2006, 108, 2929-2929.	1.4	1
238	Effects of Cord Blood Cell Subset Populations in the Development of the Dominant Cord Blood Unit in Non-Myeloablative Sequential Double Cord Blood Transplantation (DCBT).. <i>Blood</i> , 2006, 108, 3148-3148.	1.4	1
239	GM-CSF Secreting Leukemia Cell Vaccinations after Allogeneic Reduced-Intensity Peripheral Blood Stem Cell Transplantation (SCT) for Advanced Myelodysplastic Syndrome (MDS) or Refractory Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2006, 108, 3680-3680.	1.4	1
240	Chronic GVHD Is Associated with a BAFF Driven BCR-Activated B Cell Repertoire.. <i>Blood</i> , 2007, 110, 166-166.	1.4	1
241	Double Umbilical Cord Blood Transplantation with Reduced Intensity Conditioning and Sirolimus-Based GVHD Prophylaxis.. <i>Blood</i> , 2007, 110, 2016-2016.	1.4	1
242	Tacrolimus and Sirolimus without Methotrexate as Acute GVHD Prophylaxis after Matched Related Donor Reduced Intensity Conditioning (RIC) Stem Cell Transplantation (SCT).. <i>Blood</i> , 2007, 110, 3046-3046.	1.4	1
243	Outcomes of Grades II-IV Acute Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: How Much Progress Was Achieved?. <i>Blood</i> , 2015, 126, 3132-3132.	1.4	1
244	Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab. <i>Blood</i> , 2020, 136, 10-11.	1.4	1
245	Reply to J. Mehta. <i>Journal of Clinical Oncology</i> , 2009, 27, e139-e140.	1.6	0
246	Treating Inflammation and Fibrosis in Chronic GVHD: Two Birds, One ROCK. <i>Journal of Clinical Oncology</i> , 2021, 39, 1942-1945.	1.6	0
247	Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.. <i>Blood</i> , 2004, 104, 1227-1227.	1.4	0
248	High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.. <i>Blood</i> , 2004, 104, 185-185.	1.4	0
249	Allogeneic B Cell Response to H-Y Minor Histocompatibility Antigens after Donor Lymphocyte Infusion Correlates with Disease Response.. <i>Blood</i> , 2004, 104, 296-296.	1.4	0
250	Prevention of Acute GVHD with Sirolimus Does Not Abrogate the Risk of Chronic GVHD.. <i>Blood</i> , 2004, 104, 3317-3317.	1.4	0
251	Sirolimus and Tacrolimus without Methotrexate as Graft-vs.-Host Disease Prophylaxis after Matched, Unrelated Peripheral Blood Stem Cell Transplantation: Excellent GVHD Control with Low Transplant-Related Morbidity and Mortality.. <i>Blood</i> , 2005, 106, 2051-2051.	1.4	0
252	Comparison of Methotrexate- Versus Sirolimus- Containing Graft-Versus-Host Disease Prophylaxis Regimens after Myeloablative Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 1797-1797.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Costs of Complications after Allogeneic Myeloablative Stem Cell Transplantation.. Blood, 2006, 108, 2977-2977.	1.4	0
254	Long-Term Outcome of Methotrexate-Free GVHD Prophylaxis Using Sirolimus and Tacrolimus in Matched Related (MRD) and Unrelated Donor (URD) Peripheral Blood Stem Cell Transplantation (PBSCT).. Blood, 2006, 108, 757-757.	1.4	0
255	Non-Myeloablative Allogeneic Transplantation for Hodgkinâ€™s and Non-Hodgkinâ€™s Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism.. Blood, 2007, 110, 3041-3041.	1.4	0
256	Stem Cell Sources for Allogeneic Transplantation. , 2008, , 225-244.		0
257	Development of CMV-SPECIFIC Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of NaïVE CD8+ T Cells. Blood, 2008, 112, 1167-1167.	1.4	0
258	Acute Graft Versus Host Disease: Prophylaxis. , 2010, , 565-576.		0
259	Does Iron Overload Really Matter in Stem Cell Transplantation?. Blood, 2011, 118, 3029-3029.	1.4	0
260	A Disease and Stage Risk Grouping System for Patients Undergoing Allogeneic Stem Cell Transplantation. Blood, 2011, 118, 327-327.	1.4	0
261	Gastrointestinal and Hepatic Involvement in Chronic Gvhd: An Analysis From the Chronic Gvhd Consortium. Blood, 2012, 120, 1940-1940.	1.4	0
262	Autologous Whole Tumor Cell Vaccination Early After Allogeneic Stem Cell Transplantation Elicits Anti-Tumor T Cell Responses in Patients with Advanced Chronic Lymphocytic Leukemia (CLL). Blood, 2012, 120, 1892-1892.	1.4	0
263	Reconstitution Of EBV-Specific Immunity In Adult Recipients Of Double Cord Blood Transplantation Depends On SCF and IL-7 Levels and Maintenance Of a Diverse TCR Repertoire. Blood, 2013, 122, 3302-3302.	1.4	0
264	Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402. Blood, 2016, 128, 63-63.	1.4	0
265	BK Virus-Specific T Cell Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 3425-3425.	1.4	0
266	Incidence and Predictors of Hepatic Veno-Occlusive Disease after Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2018, 132, 3376-3376.	1.4	0
267	Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant. Blood, 2018, 132, 817-817.	1.4	0
268	Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Combination with Corticosteroids, Is Well-Tolerated, with Rapid Pharmacodynamic and Clinical Response in Newly Diagnosed Acute Graft-Versus-Host Disease. Blood, 2021, 138, 2891-2891.	1.4	0
269	Outcomes of IDH1- and IDH2-Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Blood, 2020, 136, 2-3.	1.4	0
270	A Review of Oral Chronic Graft-Versus-Host Disease: Considerations for dental hygiene practice.. Journal of Dental Hygiene: JDH / American Dental Hygienists' Association, 2022, 96, 6-17.	0.1	0